The content on this site is intended for healthcare professionals only
"In my view, we have a new standard of care for treatment of BRAF-mutant advanced melanoma," Prof Grant McArthur tells ecancertv at ESMO 2014.
The coBRIM study, a phase III trial examining the effectiveness of combining cobimetinib and vemurafenib to treat advanced melanoma, demonstrated a 49% reduction in the risk of progression or death in patients treated with the combined therapy.
Watch the press conference and read the news story for more.
ecancer's filming at ESMO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
GIST tumours and soft tissue sarcomas
Hormonal receptor positive breast cancer adjuvant and metastatic indications
